CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 1.7

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

Agios Pharmaceuticals, Inc.

patents

1 out of 36

Xellia Pharmaceuticals Aps

patents

Years Active: 2013-2019

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10434105 - Therapeutically active compounds and their methods of use (2019-10-08),

2. 10227371 - Polymorphs and new solid states of tiacumicin B (2019-03-12),

3. 10201543 - Therapeutically active compounds and their methods of use (2019-02-12),

4. 8912343 - Solid forms of (1r,4r)-6'-fluoro-(N, N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and sulfuric acid (2014-12-16),

5. 8895604 - Solid forms of (1r,4r)-6'-fluoro-N,N-dimethy1-4-phenyl-4′,9′-dihydro-3′ H-spiro-[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine hydrochloride (2014-11-25),

6. 8765800 - Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine (2014-07-01),

7. 8618156 - Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine (2013-12-31),

8. 8614245 - Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine (2013-12-24),

Title: The Innovative Contributions of Stefan Kluge

Introduction

Stefan Kluge is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutically active compounds. With a total of 8 patents to his name, Kluge's work has the potential to impact cancer treatment and drug formulation.

Latest Patents

Among his latest patents, Kluge has developed compounds that are useful for treating cancer. These compounds are designed to be administered to subjects in need of treatment. Additionally, he has worked on new polymorphs and solid states of Tiacumicin B. This invention includes crystallines solvates of Tiacumicin B, which are composed of various solvents such as propanol, isopropanol, acetic acid, isopropyl acetate, chlorobenzene, and methyl-ethyl-ketone. Kluge's research also introduces a new amorphous form of Tiacumicin B.

Career Highlights

Throughout his career, Kluge has been associated with prominent companies in the pharmaceutical industry. He has worked with Gruenenthal GmbH and Agios Pharmaceuticals, Inc., where he has contributed to various innovative projects. His expertise in drug development has positioned him as a valuable asset in these organizations.

Collaborations

Kluge has collaborated with notable professionals in his field, including Michael Gruss and Stefan Pruehs. These collaborations have further enhanced his research and development efforts, leading to advancements in pharmaceutical innovations.

Conclusion

Stefan Kluge's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and drug formulation.

This text is generated by artificial intelligence and may not be accurate.